FI105012B - Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi - Google Patents

Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi Download PDF

Info

Publication number
FI105012B
FI105012B FI923402A FI923402A FI105012B FI 105012 B FI105012 B FI 105012B FI 923402 A FI923402 A FI 923402A FI 923402 A FI923402 A FI 923402A FI 105012 B FI105012 B FI 105012B
Authority
FI
Finland
Prior art keywords
cyclodextrin
erythropoietin
epo
aqueous solution
hydroxypropyl
Prior art date
Application number
FI923402A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI923402A (fi
FI923402A0 (fi
Inventor
Jean Louis Mesens
Frank Jozefy Konings
Marcus Joannes Maria Noppe
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105012(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI923402A publication Critical patent/FI923402A/fi
Publication of FI923402A0 publication Critical patent/FI923402A0/fi
Application granted granted Critical
Publication of FI105012B publication Critical patent/FI105012B/fi

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
  • Perforating, Stamping-Out Or Severing By Means Other Than Cutting (AREA)
  • Processing Of Stones Or Stones Resemblance Materials (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI923402A 1990-01-29 1992-07-28 Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi FI105012B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9001987 1990-01-29
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation
PCT/EP1991/000173 WO1991011200A1 (en) 1990-01-29 1991-01-25 Improved cyclodextrin based erythropoietin formulation
EP9100173 1991-01-25

Publications (3)

Publication Number Publication Date
FI923402A FI923402A (fi) 1992-07-28
FI923402A0 FI923402A0 (fi) 1992-07-28
FI105012B true FI105012B (fi) 2000-05-31

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
FI923402A FI105012B (fi) 1990-01-29 1992-07-28 Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi

Country Status (20)

Country Link
US (1) US5376632A (ko)
EP (1) EP0513072B1 (ko)
JP (1) JP2997052B2 (ko)
KR (1) KR0183445B1 (ko)
AT (1) ATE107518T1 (ko)
AU (1) AU648061B2 (ko)
CA (1) CA2074820C (ko)
DE (1) DE69102627T2 (ko)
DK (1) DK0513072T3 (ko)
ES (1) ES2059115T3 (ko)
FI (1) FI105012B (ko)
GB (1) GB9001987D0 (ko)
HU (1) HU218213B (ko)
IE (1) IE65209B1 (ko)
IL (1) IL97019A (ko)
NO (1) NO304728B1 (ko)
NZ (1) NZ236938A (ko)
PT (1) PT96593B (ko)
WO (1) WO1991011200A1 (ko)
ZA (1) ZA91620B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
IL131959A0 (en) * 1997-03-18 2001-03-19 Roche Diagnostics Gmbh Pharmaceutical combined preparations containing erythropoietin and iron preparations
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
DK1181036T3 (da) * 1999-04-09 2008-11-24 Ortho Mcneil Pharm Inc Farmaceutiske sammensætninger af erythropoietin
WO2002011753A1 (fr) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
CN1310671C (zh) * 2001-07-09 2007-04-18 安斯泰来制药有限公司 缓释注射剂用组合物的制造方法
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
AU2004244920B2 (en) * 2003-06-10 2009-07-23 Lg Chem, Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
AU2007325576B2 (en) 2006-10-20 2013-01-10 Icos Corporation Compositions of Chk1 inhibitors
DK2590666T3 (en) * 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
NO922990L (no) 1992-07-29
NO304728B1 (no) 1999-02-08
US5376632A (en) 1994-12-27
ATE107518T1 (de) 1994-07-15
DK0513072T3 (da) 1994-08-01
IL97019A (en) 1997-07-13
PT96593A (pt) 1991-10-15
AU648061B2 (en) 1994-04-14
HU218213B (hu) 2000-06-28
DE69102627T2 (de) 1994-11-03
EP0513072A1 (en) 1992-11-19
KR0183445B1 (en) 1999-05-01
IE65209B1 (en) 1995-10-04
FI923402A (fi) 1992-07-28
DE69102627D1 (de) 1994-07-28
EP0513072B1 (en) 1994-06-22
JP2997052B2 (ja) 2000-01-11
GB9001987D0 (en) 1990-03-28
NO922990D0 (no) 1992-07-29
WO1991011200A1 (en) 1991-08-08
FI923402A0 (fi) 1992-07-28
HU9202432D0 (en) 1992-10-28
IL97019A0 (en) 1992-03-29
ES2059115T3 (es) 1994-11-01
HUT62198A (en) 1993-04-28
PT96593B (pt) 2001-06-29
JPH05503700A (ja) 1993-06-17
ZA91620B (en) 1992-10-28
CA2074820C (en) 2003-10-14
AU7149791A (en) 1991-08-21
IE910286A1 (en) 1991-07-31
CA2074820A1 (en) 1991-07-30
NZ236938A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
FI105012B (fi) Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi
Brewster et al. Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs
Irie et al. Hydroxypropylcyclodextrins in parenteral use. I: Lipid dissolution and effects on lipid transfers in vitro
JP6444548B2 (ja) スルホアルキルエーテルシクロデキストリン組成物
US10323103B2 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
EP1501496B1 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20030055023A1 (en) Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
JP5052750B2 (ja) オリゴペプチドとエーテル化シクロデキストリンを含む液体製剤
JP2015535014A (ja) アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JPH07316065A (ja) Ｆｒ９０１４６９物質製剤
US20230357451A1 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
JPH0129482B2 (ko)
JPS6131121B2 (ko)

Legal Events

Date Code Title Description
MA Patent expired